In this episode, we interview Stephen Ubl, President and CEO of PhRMA, to discuss what is happening across the industry at a time of significant change. We talk about biopharma’s continued commitment to innovation, what member companies are doing to help patients access medicines more directly, and how new tools from the organization are supporting patient affordability. We also cover the impact of policies like the IRA and MFN, along with the growing focus on PBM reform and other structural challenges in the system. It is a wide-ranging conversation about where the industry is headed and what it will take to ensure the country continues to lead the world in bringing new treatments to patients in need.
- Steve Ubl, CEO of PhRMA
- PhRMA
- PhRMA Leadership Transition
- PhRMA 3 Announcements
- Medicine Assistance Tool (MAT)
- America’s Medicines
- Jim Collins, Building Companies to Last
- FTC Settlement with Express Scripts
- IQVIA Data: Prior Authorization and Associated Delays and Denials of Branded Medication Dispensation
- Most Favored Nation Drug Pricing
- 340B Drug Pricing Program
- New York Times: How a Hospital Chain Used a Poor Neighborhood to Turn Huge Profits
- Hatch-Waxman Act
Questions or comments?
Email us at [email protected].
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.